Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles

Andrea Fodor-Kardos; Ádám Ferenc Kiss; Katalin Monostory; Tivadar Feczkó

doi:10.1039/c9ra09928j

Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles

RSC Adv. 2020 Apr 22;10(27):15893-15900. doi: 10.1039/c9ra09928j. eCollection 2020 Apr 21.

Authors

Andrea Fodor-Kardos^{1

2}, Ádám Ferenc Kiss³, Katalin Monostory³, Tivadar Feczkó^{1

2}

Affiliations

¹ Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences Magyar Tudósok Körútja 2 H-1117 Budapest Hungary tivadar.feczko@gmail.com +36-88-624000 ext. 3508.
² Research Institute of Biomolecular and Chemical Engineering, University of Pannonia Egyetem u. 10 H-8200 Veszprém Hungary.
³ Institute of Enzymology, Research Centre for Natural Sciences Magyar Tudósok Körútja 2 H-1117 Budapest Hungary.

Abstract

Interferon-beta-1a (IFN-β-1a) can diminish the symptoms of relapsing-remitting multiple sclerosis. Herein, we prepared sustained drug delivery IFN-β-1a-loaded nanoparticles by a double emulsion solvent evaporation method. Bovine serum albumin (BSA) model drug was used to optimize the preparation of nanoparticles composed of four types of poly(lactic-co-glycolic acid) (PLGA) polymers and two pegylated PLGA (PEG-PLGA) polymers. Via optimization, selected PLGA and PEG-PLGA polymers were able to entrap IFN-β-1a with high encapsulation efficiency (>95%) and low size (145 nm and 163 nm, respectively). In vitro release kinetics of BSA and IFN-β showed similar tendency for PLGA and PEG-PLGA nanoparticles, respectively. Although the drug loaded nanoparticles did not show toxicity in hepatocyte cells, mild toxic effects such as pale kidney and pyelectasis were observed in the in vivo studies.